Pending AI
Boston, US · 1 known investors
Find your way into Pending AI
Pending AI develops a drug discovery and development platform using quantum mechanics and artificial intelligence to enable pharmaceutical companies to develop medicines for any disease. The company serves pharmaceutical partners in asset co-development.
Founders & leadership
MP
Mark P. WallerinFounderMark P. Waller is the founder and CEO of Pending AI, a Sydney-based deep tech startup building a drug discovery platform that combines quantum mechanics and AI for pharmaceutical partners. He previously held a physics professorship at Shanghai University, completed his Habilitation at the University of Münster and a postdoc at a Max Planck Institute in Mülheim an der Ruhr, earned his PhD from the University of Sydney, and did his undergraduate studies at the University of Tasmania.
Investors · 1
Frequently asked questions
- What does Pending AI do?
- Pending AI develops a drug discovery and development platform using quantum mechanics and artificial intelligence to enable pharmaceutical companies to develop medicines for any disease. The company serves pharmaceutical partners in asset co-development.
- Who founded Pending AI?
- Pending AI was founded by Mark P. Waller.
- Who are Pending AI's investors?
- Pending AI's investors include Main Sequence Ventures.
- Where is Pending AI headquartered?
- Pending AI is headquartered in Boston, US.